Abstract
Introduction: Surufatinib (also known as HMPL-012, sulfatinib) is a novel oral tyrosine kinase inhibitor (TKI), which has the dual activity of anti-an......
小提示：本篇文献需要登录阅读全文，点击跳转登录
Full Text Link
